Biogen collaborator NeuroSense shares secondary PhIIb data for its ALS treatment

Neu­roSense an­nounced sec­ondary end­point da­ta for its ALS treat­ment, which is a com­bi­na­tion of the an­tibi­ot­ic ciprofloxacin and the NSAID cele­cox­ib.

In the Phase IIb PAR­A­DIGM study, 68 pa­tients re­ceived ei­ther Neu­roSense’s treat­ment or place­bo. On a scale called the re­vised Amy­otroph­ic Lat­er­al Scle­ro­sis Func­tion­al Rat­ing Scale, which mea­sures a se­ries of phys­i­cal func­tions, pa­tients who re­ceived the treat­ment did 29% bet­ter than those who re­ceived place­bo at six months, though the re­sults were not sta­tis­ti­cal­ly sig­nif­i­cant. The func­tion­al test was a sec­ondary end­point of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.